Check out the companies making headlines in premarket trading. Sunrun — Shares fell nearly 2% following a downgrade to sector perform from outperform by RBC Capital Markets. The stock on Tuesday recorded its biggest one-day loss in its history amid a sell-off in solar names. CERo Therapeutics Holdings — Stock in the immunotherapy company pulled back about 28%. On Tuesday, the U.S. Food and Drug Administration gave the company’s acute myeloid leukemia drug CER-1236 an orphan drug designation . Shares rose more than 188% on that news. Chemours — The chemical stock dropped about 1% after an updated second-quarter forecast showed weakness in a key profit metric. Chemours said it expects consolidated adjusted EBITDA — or earnings before interest, taxes, depreciation and amortization — of $215 million to $225 million for the period. Wall Street expectations called for $236 million, according to FactSet. Regencell Bioscience — Shares dropped 13% after an eyewatering move higher this week . The Hong Kong-based developer of traditional Chinese herbal treatments has said it can treat childhood ADHD and autism. Regencell jumped 30% on Tuesday, and soared 283% Monday, following a 38-for-1 stock split. It’s gained more than 59,000% this year. Oracle — The software company gained more than 1% after Guggenheim raised its price target on the stock to the highest on the Street. Analyst John DiFucci said Oracle is “on the precipice of a narrative shift that has been decades of technology innovation in the making.” Zoetis — Shares of the animal health company slipped 1% following a downgrade at Stifel to hold from buy. The firm said it expects Zoetis’ revenue growth to decelerate further amid increasing competition. Korn Ferry — Shares of the consulting firm gained about 10% after fourth-quarter results surpassed analyst estimates on the top and bottom line. Korn Ferry earned $1.32 per share, excluding items, on revenue of $712 million. Analysts polled by FactSet expected a profit of $1.26 per share and revenue of $689.9 million. Circle Internet Group — Stock in the company behind stablecoin USDC advanced 3%, after the U.S. Senate passed the GENIUS bill . The legislation is the first of its kind and establishes federal guidelines for digital dollars that are pegged to the greenback. — CNBC’s Sarah Min, Michelle Fox, Alex Harring, Fred Imbert and Jesse Pound contributed reporting.
